Your browser doesn't support javascript.
loading
TSNAdb v2.0: The Updated Version of Tumor-specific Neoantigen Database.
Wu, Jingcheng; Chen, Wenfan; Zhou, Yuxuan; Chi, Ying; Hua, Xiansheng; Wu, Jian; Gu, Xun; Chen, Shuqing; Zhou, Zhan.
Afiliación
  • Wu J; Institute of Drug Metabolism and Pharmaceutical Analysis and Zhejiang Provincial Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
  • Chen W; Institute of Drug Metabolism and Pharmaceutical Analysis and Zhejiang Provincial Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
  • Zhou Y; Institute of Drug Metabolism and Pharmaceutical Analysis and Zhejiang Provincial Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
  • Chi Y; Alibaba-Zhejiang University Joint Research Center of Future Digital Healthcare, Alibaba DAMO Academy, Hangzhou 311121, China.
  • Hua X; Alibaba-Zhejiang University Joint Research Center of Future Digital Healthcare, Alibaba DAMO Academy, Hangzhou 311121, China.
  • Wu J; The Second Affiliated Hospital of School of Medicine, and School of Public Health, Zhejiang University, Hangzhou 310058, China; Innovation Institute for Artificial Intelligence in Medicine, Zhejiang University, Hangzhou 310018, China.
  • Gu X; Department of Genetics, Development and Cell Biology, Iowa State University, Ames, IA 50011, USA.
  • Chen S; Institute of Drug Metabolism and Pharmaceutical Analysis and Zhejiang Provincial Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
  • Zhou Z; Institute of Drug Metabolism and Pharmaceutical Analysis and Zhejiang Provincial Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China; Alibaba-Zhejiang University Joint Research Center of Future Digital Healthcare, Alibaba DAMO
Genomics Proteomics Bioinformatics ; 21(2): 259-266, 2023 04.
Article en En | MEDLINE | ID: mdl-36209954
ABSTRACT
In recent years, neoantigens have been recognized as ideal targets for tumor immunotherapy. With the development of neoantigen-based tumor immunotherapy, comprehensive neoantigen databases are urgently needed to meet the growing demand for clinical studies. We have built the tumor-specific neoantigen database (TSNAdb) previously, which has attracted much attention. In this study, we provide TSNAdb v2.0, an updated version of the TSNAdb. TSNAdb v2.0 offers several new features, including (1) adopting more stringent criteria for neoantigen identification, (2) providing predicted neoantigens derived from three types of somatic mutations, and (3) collecting experimentally validated neoantigens and dividing them according to the experimental level. TSNAdb v2.0 is freely available at https//pgx.zju.edu.cn/tsnadb/.
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Antígenos de Neoplasias / Neoplasias Tipo de estudio: Prognostic_studies Idioma: En Revista: Genomics Proteomics Bioinformatics Asunto de la revista: BIOQUIMICA / GENETICA / INFORMATICA MEDICA Año: 2023 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Antígenos de Neoplasias / Neoplasias Tipo de estudio: Prognostic_studies Idioma: En Revista: Genomics Proteomics Bioinformatics Asunto de la revista: BIOQUIMICA / GENETICA / INFORMATICA MEDICA Año: 2023 Tipo del documento: Article